{"id":"NCT00473694","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)","officialTitle":"A Multicenter, Randomized, Parallel Group Comparative, Active-Controlled, Safety-assessor Blinded. Phase IIIa, Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agent of a Neuromuscular Block Induced by Maintenance Dosing of Rocuronium or Vecuronium at 1-2 PTCs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11-28","primaryCompletion":"2006-11-06","completion":"2007-01-29","firstPosted":"2007-05-15","resultsPosted":"2019-03-07","lastUpdate":"2019-03-19"},"enrollment":182,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Anesthesia, General"],"interventions":[{"type":"DRUG","name":"sugammadex","otherNames":["Org 25969","MK-8616","BRIDION®"]},{"type":"DRUG","name":"neostigmine","otherNames":["PROSTIGMIN®"]},{"type":"DRUG","name":"vecuronium","otherNames":["NORCURON®"]},{"type":"DRUG","name":"rocuronium","otherNames":["ZEMURON®"]},{"type":"DRUG","name":"glycopyrrolate","otherNames":["ROBINUL®"]}],"arms":[{"label":"rocuronium+sugammadex","type":"EXPERIMENTAL"},{"label":"rocuronium+neostigmine","type":"ACTIVE_COMPARATOR"},{"label":"vecuronium+sugammadex","type":"EXPERIMENTAL"},{"label":"vecuronium+neostigmine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the trial is to demonstrate a faster recovery from neuromuscular block (NMB) induced with rocuronium or vecuronium after reversal by 4.0 mg/kg of Org 25969 compared with reversal by 70 μg/kg of neostigmine in combination with 14 μg/kg glycopyrrolate.","primaryOutcome":{"measure":"Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Rocuronium","timeFrame":"Up to approximately 3 hours after administration of study drug","effectByArm":[{"arm":"Rocuronium+Sugammadex","deltaMin":3.28,"sd":2.4},{"arm":"Rocuronium+Neostigmine","deltaMin":55.5,"sd":27.1}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20809967","18946293"],"seeAlso":["http://www.merck.com/clinical-trials/policies-perspectives.html"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":37},"commonTop":["Procedural pain","Nausea","Incision site complication","Vomiting","Pharyngolaryngeal pain"]}}